{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:28:41Z","timestamp":1787765321753,"version":"build-2784847793"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T00:00:00Z","timestamp":1504310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T00:00:00Z","timestamp":1504310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s10637-017-0504-6","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T00:47:10Z","timestamp":1504313230000},"page":"800-812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-7001","authenticated-orcid":false,"given":"Kosei","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kagabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Mabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kamiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Yunokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikou","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,2]]},"reference":[{"key":"504_CR1","unstructured":"International Agency for Research on Cancer (2012) Estimated cancer incidence, mortality and prevalence worldwide in 2012. (http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_population.aspx)"},{"key":"504_CR2","unstructured":"Ministry of Health, Labour and Welfare (2014) Demographic statistics (http:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/kakutei14\/dl\/11_h7.pdf)"},{"key":"504_CR3","doi-asserted-by":"publisher","first-page":"viii61","DOI":"10.1093\/annonc\/mdr518","volume":"22","author":"E Pujade-Lauraine","year":"2011","unstructured":"Pujade-Lauraine E, Alexandre J (2011) Update of randomized trials in recurrent disease. Ann Oncol 22:viii61\u2013viii64","journal-title":"Ann Oncol"},{"key":"504_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1586\/era.09.54","volume":"9","author":"TH Dellinger","year":"2009","unstructured":"Dellinger TH, Monk BJ (2009) Systemic therapy for recurrent endometrial cancer: a review of north American trials. Anticancer Ther 9:905\u2013916","journal-title":"Anticancer Ther"},{"key":"504_CR5","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.suronc.2011.12.008","volume":"21","author":"M Peiretti","year":"2012","unstructured":"Peiretti M, Zapardiel I, Zanagnolo V et al (2012) Management of recurrent cervical cancer: a review of the literature. Surg Oncol 21:e59\u2013e66","journal-title":"Surg Oncol"},{"key":"504_CR6","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A, L\u00fcck HJ, Meier W et al (2003) A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320\u20131330","journal-title":"J Natl Cancer Inst"},{"key":"504_CR7","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455\u20137464","journal-title":"Oncogene"},{"key":"504_CR8","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1535-7163.MCT-12-1185","volume":"10","author":"T Hisamatsu","year":"2013","unstructured":"Hisamatsu T, Mabuchi S, Matsumoto Y (2013) Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary. Mol Cancer Ther 10:1367\u20131377","journal-title":"Mol Cancer Ther"},{"key":"504_CR9","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1158\/1078-0432.CCR-11-2485","volume":"18","author":"JK Schwarz","year":"2012","unstructured":"Schwarz JK, Payton JE, Rashmi R et al (2012) Pathway-specific analysis of gene expression data identifies the PI3K\/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res 18:1464\u20131471","journal-title":"Clin Cancer Res"},{"key":"504_CR10","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1158\/1078-0432.CCR-04-2142","volume":"11","author":"DA Levine","year":"2005","unstructured":"Levine DA, Bogomolniy F, Yee CJ et al (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11:2875\u20132878","journal-title":"Clin Cancer Res"},{"key":"504_CR11","doi-asserted-by":"publisher","first-page":"10669","DOI":"10.1158\/0008-5472.CAN-05-2620","volume":"65","author":"K Oda","year":"2005","unstructured":"Oda K, Stokoe D, Taketani Y et al (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65:10669\u201310673","journal-title":"Cancer Res"},{"key":"504_CR12","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","volume":"10","author":"F Janku","year":"2011","unstructured":"Janku F, Tsimberidou AM, Garrido-Laguna I et al (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors. Mol Cancer Ther 10:558\u2013565","journal-title":"Mol Cancer Ther"},{"key":"504_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ygyno.2005.09.047","volume":"101","author":"Y Hashiguchi","year":"2006","unstructured":"Hashiguchi Y, Tsuda H, Inoue T et al (2006) PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 101:71\u201375","journal-title":"Gynecol Oncol"},{"key":"504_CR14","doi-asserted-by":"publisher","first-page":"7518","DOI":"10.1158\/1078-0432.CCR-11-1664","volume":"17","author":"SB Korets","year":"2011","unstructured":"Korets SB, Czok S, Blank SV et al (2011) Targeting the mTOR\/4E-BP pathway in endometrial cancer. Clin Cancer Res 17:7518\u20137528","journal-title":"Clin Cancer Res"},{"key":"504_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nature12881","volume":"506","author":"AI Ojesina","year":"2014","unstructured":"Ojesina AI, Lichtenstein L, Freeman SS et al (2014) Landscape of genomic alterations in cervical carcinomas. Nature 506:371\u2013375","journal-title":"Nature"},{"key":"504_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ygyno.2012.04.006","volume":"126","author":"S Fu","year":"2012","unstructured":"Fu S, Hennessy BT, Ng CS et al (2012) Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126:47\u201353","journal-title":"Gynecol Oncol"},{"key":"504_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"504_CR18","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322","journal-title":"J Clin Oncol"},{"key":"504_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ygyno.2008.06.013","volume":"111","author":"AA Garcia","year":"2008","unstructured":"Garcia AA, Blessing JA, Nolte S et al (2008) A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the gynecologic oncology group. Gynecol Oncol 111:22\u201326","journal-title":"Gynecol Oncol"},{"key":"504_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1200\/JCO.1997.15.2.625","volume":"15","author":"CF Verschraegen","year":"1997","unstructured":"Verschraegen CF, Levy T, Kudelka AP et al (1997) Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15:625\u2013631","journal-title":"J Clin Oncol"},{"key":"504_CR21","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/1078-0432.CCR-03-0406","volume":"10","author":"L Van Ummersen","year":"2004","unstructured":"Van Ummersen L, Binger K, Volkman J et al (2004) A phase I trial of perifosine (NSC 639966) on a loading dose\/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10:7450\u20137456","journal-title":"Clin Cancer Res"},{"key":"504_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/1535-7163.MCT-10-1089","volume":"10","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K et al (2011) PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10:1093\u20131101","journal-title":"Mol Cancer Ther"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0504-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0504-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0504-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:10:12Z","timestamp":1678511412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0504-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,2]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0504-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,2]]},"assertion":[{"value":"11 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Kosei Hasegawa reports other from Yakult Honsha Co., Ltd., other from Ono Pharmaceutical Co., Ltd., other from Taiho Pharmaceutical Co., Ltd., other from Kyowa Hakko Kirin Co., Ltd., other from Chugai Pharmaceutical Co., Ltd., outside the submitted work; Daisuke Aoki reports grants from Chugai Pharmaceutical Co., Ltd., grants from Taiho Pharmaceutical Co., Ltd., personal fees from MSD K.K., personal fees from AstraZeneca K.K., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from GlaxoSmithKline K.K., personal fees from Daiichi Sankyo Co., Ltd., personal fees from Taiho Pharmaceutical Co., Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Nippon Kayaku Co., Ltd., personal fees from Becton, Dickinson and Company, personal fees from Novartis Pharma K.K., personal fees from Bristol-Myers K.K., personal fees from Janssen Pharmaceutical K.K., personal fees from Roche Diagnostics K.K., personal fees from Yakult Honsha Co., Ltd., outside the submitted work; Mayu Yunokawa reports grants from Yakult Honsha Co., Ltd., outside the submitted work; Kazunori Ochiai reports grants from Taiho Pharmaceutical Co., Ltd., grants from Zeria Pharmaceutical Co., Ltd., outside the submitted work; Tadashi Kimura reports personal fees from Yakult Honsha Co., Ltd., outside the submitted work; All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflict of interest"}},{"value":"The protocol was approved by the ethics committee of each participating institution. The trial was conducted in compliance with the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for inclusion, including in the biomarker analysis, was obtained from all patients prior to registration.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}